Takashi Kobunai
Overview
Explore the profile of Takashi Kobunai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
618
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tanaka T, Kobunai T, Yamamoto Y, Murono K, Otani K, Yasuda K, et al.
In Vivo
. 2017 Jun;
31(4):713-718.
PMID: 28652445
Aim: Mitochondrial dysfunction plays a central role in carcinogenesis in numerous cancer-related diseases. We examined the copy number variation of mitochondrial DNA (mtDNA) and the expression of energy-producing genes in...
12.
Ishida K, Ito C, Ohmori Y, Kume K, Sato K, Koizumi Y, et al.
Sci Rep
. 2017 May;
7(1):2262.
PMID: 28536445
Drug-tolerant cancer cell subpopulations are responsible for relapse after chemotherapy. By continuously exposing the gastric cancer cell line MKN45 to 5-FU for >100 passages, we established a 5-fluorouracil (5-FU)-tolerant line,...
13.
Matsusaka S, Kobunai T, Yamamoto N, Chin K, Ogura M, Tanaka G, et al.
Genes Cancer
. 2016 Mar;
7(1-2):27-35.
PMID: 27014419
Receptor tyrosine kinase (RTK)-related genes, including HER2, EGFR, MET, FGFR2 and KRAS, are target molecules that are clinically beneficial in gastric cancer (GC). We investigated the correlation between RTK-related genes...
14.
Ishikawa T, Uetake H, Murotani K, Kobunai T, Ishiguro M, Matsui S, et al.
Anticancer Res
. 2016 Mar;
36(3):853-60.
PMID: 26976971
Background: The adjuvant chemotherapy trial of TS-1 for colon cancer phase III trial was designed to validate the non-inferiority of the oral fluoropyrimidine S-1 to uracil and tegafur/leucovorin as adjuvant...
15.
Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, et al.
Am J Cancer Res
. 2015 Sep;
5(8):2431-40.
PMID: 26396918
5-Fluorouracil (5-FU) is a key drug for the treatment of esophageal squamous cell carcinoma (ESCC); however, resistance to it remains a critical limitation to its clinical use. To clarify the...
16.
Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K
Dis Colon Rectum
. 2013 Dec;
57(1):23-31.
PMID: 24316942
Background: Patients with rectal cancer exhibit a wide spectrum of responses to chemoradiotherapy. Several gene expression signatures have been reported to predict the response to chemoradiotherapy in rectal cancer, but...
17.
Nukatsuka M, Saito H, Nakagawa F, Tsujimoto H, Sakamoto K, Tsukioka S, et al.
Exp Ther Med
. 2012 Sep;
3(5):755-762.
PMID: 22969964
In this study, combination therapies using the oral fluoropyrimidine tegafur-gimeracil-oteracil (S-1) with several targeted agents or antibodies, were evaluated. First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate...
18.
Akiyoshi T, Kobunai T, Watanabe T
Surg Today
. 2012 Sep;
42(11):1037-45.
PMID: 22961195
The use of adjuvant chemotherapy for stage II colon cancer remains controversial. The accurate assessment of the risk factors associated with recurrence in patients with stage II disease is the...
19.
Nukatsuka M, Saito H, Sakamoto K, Nakagawa F, Uchida J, Kobunai T, et al.
Anticancer Res
. 2012 Jul;
32(7):2807-12.
PMID: 22753741
Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer. In this experiment, we investigated the optimal combination schedule and...
20.
Akiyoshi T, Kobunai T, Watanabe T
Surg Today
. 2012 Jun;
42(8):713-9.
PMID: 22706722
Preoperative radiotherapy or chemoradiotherapy (CRT) has become a standard treatment for patients with locally advanced rectal cancer. However, there is a wide spectrum of responses to preoperative CRT, ranging from...